Prostascint Related Published Studies
Research related to Prostascint (Capromab Pendetide)
Salvage cryosurgical ablation of the prostate for local recurrence after radiation therapy: improved outcomes utilizing a capromab pendetide scan and biopsy algorithm. [2007.12]
Biochemical disease-free survival rates following definitive low-dose-rate prostate brachytherapy with dose escalation to biologic target volumes identified with SPECT/CT capromab pendetide. [2007.01]
Role of ProstaScint for brachytherapy in localized prostate adenocarcinoma. [2004.07]
Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. [2002.02.15]
Evaluation of preoperative ProstaScint scans in the prediction of nodal disease. [2002]
Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer. The ProstaScint Imaging Centers. [2000.12.20]
Evaluation of prostate cancer patients receiving multiple staging tests, including ProstaScint scintiscans. [2000.02.01]
Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer. [1999.12]
Comparison of clinical staging algorithms and 111indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients. [1999.04.01]
A phase II study of [90Y] yttrium-capromab pendetide in the treatment of men with prostate cancer recurrence following radical prostatectomy. [1999.04]
ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients. [1998.12.01]
111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group. [1998.06]
Capromab pendetide. A review of its use as an imaging agent in prostate cancer. [1998.04]
Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy. [1998.01]
Comparison of serum PSMA, PSA levels with results of Cytogen-356 ProstaScint scanning in prostatic cancer patients. [1997.12.01]
Technical considerations for acquiring and processing indium-111 capromab pendetide images. [1997.09]
Other possibly related research studies
Rectal morbidity after permanent prostate brachytherapy with dose escalation to biologic target volumes identified by SPECT/CT fusion. [2007.04]
Synergistic value of single-photon emission computed tomography/computed tomography fusion to radioimmunoscintigraphic imaging of prostate cancer. [2007.01]
Therapy with immunoglobulin: applications for monoclonal antibodies. [2006.05]
Correction of photon attenuation and collimator response for a body-contouring SPECT/CT imaging system. [2005.05]
Biochemical recurrence after definitive prostate cancer therapy. Part II: treatment strategies for biochemical recurrence of prostate cancer. [2005.05]
Combination conformal radiotherapy and radioimmunoguided transperineal 103Pd implantation for patients with intermediate and unfavorable risk prostate adenocarcinoma. [2003]
Four-year biochemical outcome after radioimmunoguided transperineal brachytherapy for patients with prostate adenocarcinoma. [2003.10.01]
PSMA specific antibodies and their diagnostic and therapeutic use. [2001.03]
Feasibility and acute toxicities of radioimmunoguided prostate brachytherapy. [2000.10.01]
In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. [2000.09.15]
Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment. [1999.04.01]
Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. [1999.01.01]
The role of monoclonal antibody in the management of prostate adenocarcinoma. [1998.12]
Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. [1998.06.15]
Prostate-specific membrane antigen: current and future utility. [1998.02]
Trials and tribulations: oncological antibody imaging comes to the fore. [1997.01]
Monoclonal antibody imaging of occult prostate cancer in patients with elevated prostate-specific antigen. Positron emission tomography and biopsy correlation. [1996.09]
Radiation absorbed dose from indium-111-CYT-356. [1996.09]
Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody. [1996.08]
|
